GlassScriptPhysician profile
Max Christopher Kupferman
NPI 1629643028
$11,246.68
in general payments reported to CMS, 2019-2025
34 companies · $2,500 in 2025
The $2,500 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,525 · 2022: $1,852 · 2023: $2,614 · 2024: $2,755 · 2025: $2,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,869.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,543.96 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,099.79 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $830.76 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $822.61 | 2021-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $807.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $755.16 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Axsome Therapeutics, INC. | $737.52 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $639.14 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $598.69 | 2021-2025 | |
| Alkermes, INC. | $496.65 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $458.51 | 2022-2025 | Rexulti |
| Bausch Health US, LLC | $395.64 | 2021-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $310.27 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $285.50 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $236.49 | 2021-2025 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $222.69 | 2021-2024 | Jornay Pm |
| Corium, LLC | $140.06 | 2023-2025 | Azstarys |
| Biogen, INC. | $135.70 | 2023-2025 | Zurzuvae |
| Indivior INC. | $111.84 | 2021-2025 | Perseris, Sublocade |
| Livanova USA, INC. | $88.23 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $81.52 | 2021-2025 | Xelstrym, Secuado |
| Alfasigma USA, INC. | $69.09 | 2021 | |
| Adlon Therapeutics L.P. | $55.52 | 2021 | |
| Tempus Ai, INC | $51.24 | 2024 | |
| Tris Pharma INC | $40.14 | 2023-2024 | Dyanavel Xr |
| Pfizer INC. | $39.31 | 2023 | |
| Vertical Pharmaceuticals, LLC | $35.84 | 2024 | Relexxii |
| Eisai INC. | $25.91 | 2021 | |
| Almatica Pharma LLC | $25.09 | 2022 | |
| Jazz Pharmaceuticals INC. | $25.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $23.07 | 2025 | Jornay Pm |
| Biohaven Pharmaceutical Holding Company LTD. | $22.94 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.06 | 2025 | Rejoyn |
| Neos Therapeutics, LP | $15.23 | 2025 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Kupferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.